Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

S*BIO Lands Another $20 Million from Onyx

publication date: May 5, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
S*BIO Pte Ltd., a clinical stage Singapore biotech, has signed a new $20 million deal with Onyx Pharmaceuticals to expand the development of S*BIO's novel JAK2 inhibitors, SB1518 and SB1578. S*BIO will use the money to explore new indications for hematologic malignancies and myeloproliferative disorders. The two companies signed their original $25 million agreement in January 2009. More details...

Stock Symbol: (NSDQ: ONXX)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...